The British Medical Journal is being urged by health policy researchers from University of Otago's Dunedin and Christchurch campuses to adopt a more even handed approach in scrutinizing the transparency of what it publishes.
Professor Robin Gauld, the Director of the Centre for Health Systems, has co-written a letter that has appeared in the BMJ on 31 May, expressing concern about a journal editorial reviewing a report into the performance of the Canterbury District Health Board (CDHB) prepared by the King's Fund in England.
Clinical Trials
Clinical trials are experiments that yield useful information to clinicians if a particular treatment is of any value to a patient.
Advertisement
The report, released in September 2013, talks about the 'impressive progress' of the CDHB since the 2010 and 2011 earthquakes, but Gauld says it turns out the board paid NZD $186,000 for the King's Fund to produce the document.
"This funding was not revealed in the report and in its editorial the BMJ seems to have simply accepted the findings as independent, with no disclosure of the CDHB's involvement," he says.
![Clinical Trials - The Past and The Future]( "Clinical Trials - The Past and The Future")
Many of the drugs that are used today have been discovered by chance or often by mere serendipity
"The BMJ has always been a champion of transparency when it comes to funding and other conflicts of interest. If we were submitting such a report we would have to declare funding sources and potential conflicts of interest - right down to saying which conferences we had attended and who paid for them.
"Those principles of transparency and independence have not been applied here."
In the letter to the BMJ Professor Gauld and his colleagues Antony Raymont, Phil Bagshaw, Gary Nicholls and Chris Frampton, say the King's Fund may have reported some useful lessons for those interested in health system integration but, unfortunately, it did not acknowledge among other less positive indicators the level of ongoing unmet need for health care in Canterbury.
"Rather, as in the case of the pharmaceutical industry, notorious for selective reporting of clinical trials, we believe public perception has been manipulated. A transparency protocol for reports such as the King's Fund's and Editorials on them would, in future, reduce this possibility."
Professor Gauld says such a protocol could be developed and extended to other publications by way of the International Committee of Medical Journal Editors.
Source: Eurekalert
Clinical Trials - The Past and The Future
Many of the drugs that are used today have been discovered by chance or often by mere serendipity
Advertisement
"The BMJ has always been a champion of transparency when it comes to funding and other conflicts of interest. If we were submitting such a report we would have to declare funding sources and potential conflicts of interest - right down to saying which conferences we had attended and who paid for them.
"Those principles of transparency and independence have not been applied here."
In the letter to the BMJ Professor Gauld and his colleagues Antony Raymont, Phil Bagshaw, Gary Nicholls and Chris Frampton, say the King's Fund may have reported some useful lessons for those interested in health system integration but, unfortunately, it did not acknowledge among other less positive indicators the level of ongoing unmet need for health care in Canterbury.
"Rather, as in the case of the pharmaceutical industry, notorious for selective reporting of clinical trials, we believe public perception has been manipulated. A transparency protocol for reports such as the King's Fund's and Editorials on them would, in future, reduce this possibility."
Professor Gauld says such a protocol could be developed and extended to other publications by way of the International Committee of Medical Journal Editors.
Source: Eurekalert
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care.
Advertisement
Advertisement
|
Advertisement
Latest Clinical Trials News
Erdafitinib is the first approved FGFR-targeted treatment for advanced urothelial cancer, reveal scientists.
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.